New York, NY, United States
New York, NY, United States

Time filter

Source Type

Patent
ZIOPHARM Oncology | Date: 2013-03-12

The present invention relates to pharmaceutical formulations that increase the solubility and bioavailability of indibulin, such as a spray-dried solid dispersion of indibulin with at least one matrix polymer. The invention further provides dosage formulations comprising the dispersion and processes for making the dispersion. The present invention also discloses a method of treating immune system based disorders, hyper-proliferative disorders, angiogenesis, malignancies, and neoplasms with the indibulin formulations disclosed herein.


Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and A^(+) is an ammonium cation.


Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and A^(+) is an ammonium cation.


Patent
ZIOPHARM Oncology | Date: 2013-08-02

The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.


Patent
ZIOPHARM Oncology | Date: 2013-11-06

Disclosed herein are crystalline compounds of formula (I)


Patent
ZIOPHARM Oncology | Date: 2013-04-17

Disclosed herein are crystalline compounds of formula (I), wherein A^(+) represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.


Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and A^(+) is an ammonium cation.


In one aspect, a method for treating a subject having a hyperproliferative disorder is disclosed, including administering to the subject a composition including: IPM, an IPM analog, or a pharmaceutically acceptable salt thereof in the dosage from about 70 mg/m^(2)/day to about 160 mg/m^(2)/day; etoposide in the dosage up to about 100 mg/m^(2)/day; and one or more of carboplatin, cisplatin, oxaliplatin, picoplatin, or a combination thereof in the dosage of from AUC 2 mg/mL/min to AUC 7 mg/mL/min; wherein the treatment does not result in a dose limiting toxicity.


Patent
ZIOPHARM Oncology | Date: 2013-08-15

The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as Indibulin, and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.


The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein A^(+) represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyper-proliferative disorders, also are disclosed.

Loading ZIOPHARM Oncology collaborators
Loading ZIOPHARM Oncology collaborators